{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:58:09Z","timestamp":1790398689087,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.clim.2018.03.004","type":"journal-article","created":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T17:56:51Z","timestamp":1520877411000},"page":"9-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"special_numbering":"C","title":["Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies"],"prefix":"10.1016","volume":"206","author":[{"given":"Konstantinos H.","family":"Katsanos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Papamichael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Feuerstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios K.","family":"Christodoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Cheifetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2018.03.004_bb0005","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease","volume":"361","author":"Abraham","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.03.004_bb0010","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/apt.14338","article-title":"Review article: changes in the epidemiology of inflammatory bowel disease-clues for aetiology","volume":"46","author":"Bernstein","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.clim.2018.03.004_bb0015","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature06005","article-title":"Unraveling the pathogenesis of inflammatory bowel disease","volume":"448","author":"Xavier","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.clim.2018.03.004_bb0020","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrgastro.2016.208","article-title":"Current and emerging therapeutic targets for IBD","volume":"14","author":"Neurath","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.clim.2018.03.004_bb0025","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/j.1365-2036.2011.04599.x","article-title":"Review article: remission rates achievable by current therapies for inflammatory bowel disease","volume":"33","author":"Peyrin-Biroulet","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.clim.2018.03.004_bb0030","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/MIB.0000000000000202","article-title":"Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse","volume":"21","author":"Papamichael","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.clim.2018.03.004_bb0035","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohn's disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.clim.2018.03.004_bb0040","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.clim.2018.03.004_bb0045","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2016.04.039","article-title":"Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis","volume":"14","author":"Bonovas","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.clim.2018.03.004_bb0050","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/apt.12639","article-title":"Review article: anti-adhesion therapies for inflammatory bowel disease","volume":"39","author":"Lobat\u00f3n","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.clim.2018.03.004_bb0055","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2147\/CEG.S110546","article-title":"Next generation of biologics for the treatment of Crohn's disease: an evidence-based review on ustekinumab","volume":"10","author":"Jauregui-Amezaga","year":"2017","journal-title":"Clin. Exp. Gastroenterol."},{"key":"10.1016\/j.clim.2018.03.004_bb0060","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/gutjnl-2011-300904","article-title":"New therapies for inflammatory bowel disease: from the bench to the bedside","volume":"61","author":"Danese","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.clim.2018.03.004_bb0065","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/gutjnl-2016-312912","article-title":"Next generation of small molecules in inflammatory bowel disease","volume":"66","author":"Olivera","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.clim.2018.03.004_bb0070","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn's disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.03.004_bb0075","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clim.2018.03.004_bb0080","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1097\/MIB.0000000000000373","article-title":"Efficacy and safety of natalizumab and vedolizumab for the management of Crohn's disease: a systematic review and meta-analysis","volume":"21","author":"Chandar","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.clim.2018.03.004_bb0085","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease","volume":"353","author":"Van Assche","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.03.004_bb0090","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.03.004_bb0095","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.03.004_bb0100","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.cgh.2008.06.007","article-title":"Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin","volume":"6","author":"Feagan","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.clim.2018.03.004_bb0105","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa042982","article-title":"Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin","volume":"352","author":"Feagan","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.03.004_bb0110","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"GEMINI 1 study group. Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.03.004_bb0115","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.03.004_bb0120","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clim.2018.03.004_bb0125","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/MIB.0000000000000396","article-title":"Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis","volume":"21","author":"Mosli","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.clim.2018.03.004_bb0130","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.cgh.2016.02.016","article-title":"Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease","volume":"14","author":"Amiot","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.clim.2018.03.004_bb0135","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1097\/MIB.0b013e318281f538","article-title":"Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease","volume":"19","author":"Parikh","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.clim.2018.03.004_bb0140","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn's disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.clim.2018.03.004_bb0145","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/apt.13215","article-title":"Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease","volume":"41","author":"Luthra","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.clim.2018.03.004_bb0150","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1136\/gutjnl-2016-312439","article-title":"Blockade of \u03b1E\u03b27 integrin suppresses accumulation of CD8(+) and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo","volume":"66","author":"Zundler","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.clim.2018.03.004_bb0155","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/j.1476-5381.2011.01205.x","article-title":"A humanized monoclonal antibody targeting the b7 integrin selectively blocks intestinal homing of T lymphocytes","volume":"162","author":"Stefanich","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.clim.2018.03.004_bb0160","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1136\/gutjnl-2011-301769","article-title":"A randomised phase I study of etrolizumab (rhuMAb b7) in moderate to severe ulcerative colitis","volume":"62","author":"Rutgeerts","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.clim.2018.03.004_bb0165","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(14)60661-9","article-title":"Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial","volume":"384","author":"Vermeire","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2018.03.004_bb0170","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.gastro.2015.10.041","article-title":"Association between response to etrolizumab and expression of integrin alphaE and Granzyme A in colon biopsies of patients with ulcerative colitis","volume":"150","author":"Tew","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clim.2018.03.004_bb0175","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2036.2004.01863.x","article-title":"An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis","volume":"19","author":"Miner","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.clim.2018.03.004_bb0180","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1053\/j.gastro.2015.08.044","article-title":"Safety and efficacy of AJM300, an oral antagonist of alpha4 integrin, in induction therapy for patients with active ulcerative colitis","volume":"149","author":"Yoshimura","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clim.2018.03.004_bb0185","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/gut.2010.226548","article-title":"The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study","volume":"60","author":"Vermeire","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.clim.2018.03.004_bb0190","first-page":"1068","article-title":"Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study","volume":"60","author":"Sandborn","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.clim.2018.03.004_bb0195","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(17)30930-3","article-title":"Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomized, double-blind, placebo-controlled trial","volume":"390","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.clim.2018.03.004_bb0200","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/ecco-jcc\/jjx128","article-title":"Effect of PF-00547659 on central nervous system immune surveillance and circulating \u03b27+ T Cells in Crohn's disease: Report of the TOSCA study: MADCAM-1 antibody and CNS immune surveillance","volume":"12","author":"D'Haens","year":"2018","journal-title":"J. Crohns. Colitis."},{"key":"10.1016\/j.clim.2018.03.004_bb0205","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.2147\/DDDT.S102141","article-title":"Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy","volume":"10","author":"Deepak","year":"2016","journal-title":"Drug. Des. Devel. Ther."},{"key":"10.1016\/j.clim.2018.03.004_bb0210","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"CERTIFI study group. Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.03.004_bb0215","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.03.004_bb0220","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.cgh.2015.09.018","article-title":"Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn's disease refractory to anti-tumor necrosis factor agents","volume":"14","author":"Wils","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.clim.2018.03.004_bb0225","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","article-title":"Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled phase 2 study","volume":"289","author":"Feagan","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2018.03.004_bb0230","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.gastro.2017.03.049","article-title":"Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn's disease: a phase 2a study","volume":"153","author":"Sands","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clim.2018.03.004_bb0235","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signalling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.clim.2018.03.004_bb0240","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.03.004_bb0245","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.03.004_bb0250","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2018.03.004_bb0255","doi-asserted-by":"crossref","first-page":"S1308","DOI":"10.1016\/S0016-5085(17)34357-3","article-title":"Safety and efficacy of ABT-494 (Upadacitinib), an oral JAK1 inhibitor, as induction therapy in patients with Crohn's disease: Results from CELEST","volume":"152","author":"Sandborn","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clim.2018.03.004_bb0260","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis","volume":"374","author":"Sandborn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.03.004_bb0265","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1136\/gutjnl-2014-307118","article-title":"A phase II study of laquinimod in Crohn's disease","volume":"64","author":"D'Haens","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.clim.2018.03.004_bb0270","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.cgh.2015.11.014","article-title":"Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis","volume":"14","author":"Papamichael","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.clim.2018.03.004_bb0275","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/ecco-jcc\/jjw122","article-title":"Post-induction adalimumab concentration is associated with short-term mucosal healing in patients with ulcerative colitis","volume":"11","author":"Papamichael","year":"2017","journal-title":"J. Crohns. Colitis."},{"key":"10.1016\/j.clim.2018.03.004_bb0280","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.cgh.2017.03.031","article-title":"Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab","volume":"15","author":"Papamichael","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.clim.2018.03.004_bb0285","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/apt.14124","article-title":"Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors","volume":"46","author":"Ward","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.clim.2018.03.004_bb0290","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cgh.2015.10.025","article-title":"B, et al., optimizing anti-TNF-\u03b1 therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases","volume":"14","author":"Ungar","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.clim.2018.03.004_bb0295","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.cgh.2016.11.023","article-title":"Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases and need for additional doses within 6\u202fmonths","volume":"15","author":"Williet","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.clim.2018.03.004_bb0300","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.cgh.2017.03.032","article-title":"Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn's disease","volume":"15","author":"Battat","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.clim.2018.03.004_bb0305","first-page":"556","article-title":"Overview of therapeutic drug monitoring of biologic agents in patients with inflammatory bowel disease","volume":"13","author":"Cheifetz","year":"2017","journal-title":"Gastroenterol. Hepatol. (NY)."},{"key":"10.1016\/j.clim.2018.03.004_bb0310","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/ajg.2017.21","article-title":"Therapeutic drug monitoring in IBD: the new standard-of-care for anti-TNF therapy","volume":"112","author":"Papamichael","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.clim.2018.03.004_bb0315","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clim.2018.03.004_bb0320","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1097\/MIB.0000000000000156","article-title":"Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study","volume":"20","author":"Vaughn","year":"2014","journal-title":"Inflamm. Bowel Dis."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661617309014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661617309014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T20:53:53Z","timestamp":1567803233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661617309014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":64,"alternative-id":["S1521661617309014"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2018.03.004","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2018.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}